Healthcare Industry News: skin cancer
News Release - November 11, 2008
Cardium's InnerCool Announces New Tissue-Specific UroCool(TM) System for Use in Prostate SurgeriesNew Data Suggest Potential Benefits of Targeted Tissue Cooling During Prostate Surgery
SAN DIEGO, Nov. 11 (Healthcare Sales & Marketing Network) -- Cardium Therapeutics (Amex: CXM ) and its operating unit InnerCool Therapies, Inc., today announced that it has developed a pelvic cooling catheter system called UroCool(TM), which is designed to induce localized cooling during surgery for prostate cancer (radical prostatectomy). The new technology is being applied in collaboration with renowned prostate surgeon, Thomas E. Ahlering, M.D., Professor and Vice Chair of the Department of Urology at the University of California, Irvine and is the subject of an exclusive licensing agreement with the University of California. A regulatory application for FDA 510(k) clearance of InnerCool's UroCool(TM) catheter is expected to be submitted in the first quarter of 2009.
Dr. Ahlering and his colleague Dr. David S. Finley are conducting clinical studies designed to demonstrate safety and confirm the potential benefits of localized cooling during robotic-assisted prostatectomy, which is now the most common surgical technique for prostate cancer. The UroCool(TM) catheter is designed to be placed within the rectal cavity adjacent to the prostate during surgery. UroCool is used in conjunction with InnerCool's Celsius Control Console which circulates cold saline in a closed loop within the catheter to allow for localized cooling. Drs. Ahlering and Finley believe that therapeutic cooling during prostate surgery (which includes both traditional open surgical approaches and the newer robotic-assisted technique) can reduce tissue damage and inflammation and thereby provide a faster return of bladder control (continence) and possibly erectile function (potency). From a practical viewpoint, they liken this concept to icing a severely sprained ankle in order to minimize tissue injury and shorten the recovery process.
InnerCool's UroCool(TM) catheter is being incorporated into ongoing clinical studies at the University of California, Irvine, which are designed to provide additional information regarding the safety and usefulness of cooling during robotic-assisted prostate surgery. Dr. Ahlering, who is conducting the clinical studies, is an expert in the field of prostate surgery, particularly in the rapidly expanding use of robotic-assisted prostatectomy systems such as the da Vinci® system, which is a product of Intuitive Surgical, Inc.
"Our findings using localized cooling techniques during robotic-assisted radical prostatectomy surgery indicate that cooling resulted in a statistically significant faster recovery of urinary continence following surgery," noted Dr. Ahlering. "In addition, based on my surgical experience with therapeutic cooling, I believe that our ongoing studies may offer the potential to demonstrate improved post-operative erectile function for patients as well." Drs. Ahlering and Finley's clinical data on hypothermic radical prostatectomy was recently presented with an award at the European Robotic Urologic Symposium in Prague and their findings are now being published as a Rapid Review in the medical journal Urology (in press). Their data will also be presented at a number of U.S. and international urological meetings over the remainder of 2008 and early 2009.
"InnerCool has now developed a specialized tissue-specific cooling catheter that is being developed to work with InnerCool's current Celsius Control Console which has been marketed and sold since 2003," stated Christopher J. Reinhard, Chairman and Chief Executive Officer of Cardium Therapeutics and InnerCool Therapies. "The new UroCool system may provide an important opportunity to potentially enhance patient recovery of urinary control and erectile function following prostate surgery. These side effects of prostate surgery are serious, profound and frequent, and all too often patients defer proper surgical treatment because of these quality-of-life issues, underscoring the importance of new therapeutic approaches."
"We are continuing to develop a portfolio of uniquely positioned medical devices employing our platform technology and expertise in the growing field of temperature modulation therapy," added Reinhard. "These new products, like UroCool, are being developed for specific and defined vertical market opportunities for companies having established sales and marketing organizations, and we plan to structure these vertical market opportunities through strategic alignments, financings and other transactions in keeping with our ongoing strategy to leverage and monetize Cardium's InnerCool investment."
According to the American Cancer Society, prostate cancer is the most common cancer in American men other than skin cancers. One in six men will develop prostate cancer in their lifetime, and in 2007 over 200,000 men were newly diagnosed with the disease. Fortunately, prostate cancer grows relatively slowly and 7 out of 10 men are diagnosed in the early stages of the disease before it has spread to other parts of their body, thus leading to significantly increased survival with proper treatment. While the underlying cause for the development of prostate cancer is still unknown, factors such as age, race, and lifestyle affect the probability of developing the disease. Of these, age is the strongest risk factor, and as life spans continue to increase, more men are surviving to an age at which prostate cancer is more prevalent. The chances of developing prostate cancer increases quickly after reaching age 50, and about 2 out of every 3 prostate cancers are found in men over the age of 65. The three treatment approaches to prostate cancer are 'watchful waiting,' radiation, or surgery, depending on patient age, and how advanced the disease is.
Radical prostatectomy is an effective means of eradicating prostate cancer by surgically removing the entire prostate and surrounding tissue. It is a complex procedure because the prostate gland is located deep inside the pelvis and is intimately associated with delicate nerves that control erections and bladder control. Historically, radical prostatectomy has been performed as an open procedure requiring surgical precision to preserve these important functions. Robot-assisted laparoscopic radical prostatectomy emerged with the introduction of systems such as the da Vinci® Surgical System (a product of Intuitive Surgical, Inc.), which is minimally invasive and enables a high degree of precision. Since 2000, over 900 of such systems have been installed in hospitals worldwide, of which more than 700 are located in North America. Estimates show that more than 90,000 radical prostatectomies were performed in 2007 in the United States. Currently it is estimated that more than 70% of radical prostatectomies are performed robotically.
Post-Operative Incontinence and Erectile Dysfunction
Urinary incontinence and erectile dysfunction are very common side effects following open or robotic radical prostatectomy. Temporary loss of bladder control occurs in most men. While most eventually regain full control, this can take up to a year. This extended lack of urinary control is the most bothersome patient-reported side effect of prostate surgery. In addition to incontinence, many men experience some degree of erectile dysfunction following radical prostatectomy, depending on a number of factors including how potent the patient was prior to surgery, patient age, tumor stage, and how the neurovascular bundles were preserved during surgery. This side-effect is a frustrating and inconvenient experience. In many cases, the recovery of sexual function can take up to 24 months.
Additional Targeted Tissue Cooling
In addition to use in radical prostatectomies, targeted tissue cooling as developed for the UroCool catheter has a number of potential future clinical applications for tissue cooling in the pelvic region. These include other urological procedures such as radical cystectomy, a common procedure used to treat bladder cancer that has spread into the bladder wall. There are also a number of gynecological and colorectal cooling opportunities, including radical hysterectomy, myomectomy for removing fibroids from the uterus, and various types of transvaginal surgery.
Cardium Therapeutics, Inc. and its subsidiaries, InnerCool Therapies, Inc. and the Tissue Repair Company, are medical technology companies primarily focused on the development, manufacture and sale of innovative therapeutic products and devices for cardiovascular, ischemic and related indications.
Cardium's InnerCool Therapies subsidiary is a San Diego-based medical technology company in the emerging field of temperature modulation therapy to rapidly and controllably cool the body in order to reduce cell death and damage following acute ischemic events such as cardiac arrest or stroke, and to potentially lessen or prevent associated injuries such as adverse neurological outcomes. For more information about Cardium's InnerCool subsidiary and patient temperature modulation, including InnerCool's new RapidBlue(TM) System, which just received FDA clearance, and its CoolBlue(TM) System, please visit http://www.innercool.com.
Cardium also has two biologic candidates in clinical development. Cardium's Tissue Repair Company subsidiary (TRC) is focused on the development of growth factor therapeutics for the treatment of severe chronic diabetic wounds. TRC's lead product candidate, Excellarate(TM), is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-BB (PDGF-BB). Excellarate(TM) is initially being developed to be administered once or twice for the potential treatment of non-healing diabetic foot ulcers. Other potential applications for TRC's Gene Activated Matrix(TM) (GAM) technology include therapeutic angiogenesis (cardiovascular ischemia, peripheral arterial disease) and orthopedic products, including hard tissue (bone) and soft tissue (ligament, tendon, cartilage) repair. For more information about Cardium's Tissue Repair Company subsidiary, please visit http://www.t-r-co.com.
Cardium's Generx product candidate (alferminogene tadenovec, Ad5FGF-4) is a DNA-based growth factor therapeutic being developed for potential use by interventional cardiologists as a one-time treatment to promote and stimulate the growth of collateral circulation in the hearts of patients with ischemic conditions such as recurrent angina. For more information about Cardium Therapeutics and its businesses, products and therapeutic candidates, please visit http://www.cardiumthx.com/ or view its 2007 Annual Report at http://www.cardiumthx.com/flash/pdf/CardiumAR07_Book_FINAL.pdf.
Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations. For example, there can be no assurance that results observed in one study or using one type of product or procedure will be replicated in subsequent studies or in studies using newly-developed products or procedures, that planned product development efforts and clinical studies can be performed in an efficient and effective manner, that regulatory approvals can be obtained in a timely manner or at all, that partnering, distribution or other commercialization efforts can be achieved and if so that they will effectively accelerate InnerCool's patient temperature modulation business or market, that product modifications or launches will be successful or that the resulting products will be favorably received in the marketplace, that our products or proposed products will prove to be sufficiently safe and effective, that our products or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive, that results or trends observed in one clinical study will be reproduced in subsequent studies, that third parties on whom we depend will behave as anticipated, or that necessary regulatory approvals will be obtained. Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development, testing and marketing of therapeutic hypothermia devices and the conduct of human clinical trials, including the timing, costs and outcomes of such trials, whether our efforts to launch new devices and systems and expand our markets will be successful or completed within the time frames contemplated, our dependence upon proprietary technology, our ability to obtain necessary funding, regulatory approvals and qualifications, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings we make with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward- looking statements to reflect events or circumstances arising after the date hereof.
Copyright 2008 Cardium Therapeutics, Inc. All rights reserved.
Cardium Therapeutics(TM) and Generx(TM) are trademarks of Cardium Therapeutics, Inc.
Tissue Repair(TM), Gene Activated Matrix(TM), GAM(TM) and Excellarate(TM) are trademarks of Tissue Repair Company.
InnerCool Therapies®, InnerCool®, Celsius Control System®,
RapidBlue(TM), CoolBlue(TM). Accutrol®, Temperature Control Element® and
TCE® and UroCool(TM) are trademarks of InnerCool Therapies, Inc.
(other trademarks belong to their respective owners)
Source: Cardium Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.